Decoding PTEN regulation in clear cell renal cell carcinoma: Pathway for biomarker discovery and therapeutic insights

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Renal cell carcinoma (RCC) is the most common adult renal solid tumor and the deadliest urological cancer.
• Clear cell renal cell carcinoma (ccRCC) is the predominant subtype, characterized by aggressive phenotypes and therapeutic resistance.
• The PI3K/AKT signaling pathway is critically involved in ccRCC tumorigenesis, with abnormal activation leading to poor prognosis.

Purpose of the Study:

• To review the molecular mechanisms underlying PTEN suppression in ccRCC.
• To highlight the prognostic, predictive, and therapeutic potential of understanding PTEN's role in ccRCC.
• To identify potential biomarkers and therapeutic targets for improved ccRCC management.

Main Methods:

• Literature review of molecular mechanisms of PTEN inactivation in ccRCC.
• Analysis of the role of PTEN as an antagonist of the PI3K/AKT signaling axis.
• Synthesis of information on PTEN's impact on ccRCC progression and patient outcomes.

Main Results:

• PTEN loss or inactivation is frequently observed in ccRCC, contributing to aggressive tumor behavior.
• PTEN acts as a crucial tumor suppressor by antagonizing the PI3K/AKT pathway.
• Understanding PTEN mechanisms can reveal vulnerabilities in ccRCC.

Conclusions:

• PTEN suppression is a significant driver of ccRCC progression and treatment resistance.
• Targeting PTEN pathways or understanding its inactivation mechanisms may offer new therapeutic strategies.
• Further research into PTEN's role is essential for improving ccRCC patient monitoring and treatment outcomes.